Bio Green Med Solution, Inc. (BGMS) Income Statement
BGMS 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsBGMS revenue and net income
Where BGMS's revenue goes
2025Each bar shows an amount and its share of revenue. BGMS kept −401.3% of revenue as net income.
BGMS profit margins
BGMS growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +1,637.2% | — | — | −9.1% |
| Gross profit | +220.9% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
BGMS quarterly EPS vs estimates
Bio Green Med Solution beat the analyst EPS estimate in 4 of the last 4 quarters. Next report: November 12, 2026.
BGMS income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $747,000 | $43,000 | $420,000 | $0 | $0 | $0 | $0 | $150,000 | $0 | $843,000 |
| Cost of revenue | $609,000 | $6,000 | $31,000 | $32,000 | $43,000 | $20,000 | $4.7M | $4.3M | $4.2M | $9.5M |
| Gross profit | $138,000 | $43,000 | $420,000 | −$32,000 | −$43,000 | −$20,000 | −$4.7M | −$4.2M | −$4.2M | −$8.6M |
| Research & development | $848,000 | $6.7M | $19.2M | $20.3M | $14.9M | $4.7M | $4.7M | $4.3M | $4.2M | $9.5M |
| Sales, general & admin | $7.7M | $5.4M | $6.7M | $7.4M | $7.5M | $5.9M | $5.0M | $5.4M | $5.3M | $5.5M |
| Total operating expenses | $8.6M | $12.0M | $25.9M | $27.7M | $22.4M | $10.6M | $5.0M | $5.4M | $5.3M | $5.5M |
| Operating income | −$8.4M | −$12.0M | −$25.5M | −$27.7M | −$22.4M | −$10.6M | −$9.7M | −$9.5M | −$9.5M | −$14.2M |
| Interest income | $62,000 | $12,000 | $266,000 | $210,000 | $16,000 | — | — | — | — | — |
| Income before taxes | −$3.0M | −$12.0M | −$25.6M | −$25.9M | −$22.2M | −$9.7M | −$9.1M | −$8.6M | −$8.5M | −$13.8M |
| Income taxes | $7,000 | −$782,000 | −$3.0M | −$4.7M | −$3.7M | −$1.2M | $1.3M | $1.3M | $993,000 | $2.0M |
| Net income | −$3.0M | −$11.2M | −$22.6M | −$21.2M | −$18.5M | −$8.4M | −$7.8M | −$7.3M | −$7.5M | −$11.8M |
| EBITDA | −$8.4M | −$12.0M | −$25.4M | −$27.6M | −$22.3M | −$9.7M | −$9.7M | −$9.5M | −$9.5M | −$14.0M |
| EPS (diluted) | −$0.65 | −$291.22 | −$6535.31 | −$4680.60 | −$5760.54 | −$9109.33 | −$25922.77 | −$33123.17 | −$22.28 | −$259009.70 |
| Gross margin | 18.5% | 100.0% | 100.0% | — | — | — | — | −2,784.7% | — | −1,024.2% |
| Operating margin | −1,128.1% | −27,916.3% | −6,060.2% | — | — | — | — | −6,365.3% | — | −1,678.5% |
| Net margin | −401.3% | −26,074.4% | −5,370.2% | — | — | — | — | −4,858.7% | — | −1,398.7% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $336,000 | $778,000 | $666,000 | $81,000 | $0 | $0 | $0 | $10,000 | $4,000 | $29,000 | $31,000 | $16,000 |
| Cost of revenue | $257,000 | $635,000 | $545,000 | $64,000 | $1,000 | $0 | $1,000 | $1,000 | $2,000 | $2,000 | $8,000 | $7,000 |
| Gross profit | $79,000 | $143,000 | $121,000 | $17,000 | −$1,000 | $0 | −$1,000 | $10,000 | $4,000 | $27,000 | $23,000 | $9,000 |
| Research & development | — | $1,000 | $47,000 | $5,000 | $67,000 | $822,000 | $880,000 | $950,000 | $2.0M | $5.7M | $3.9M | $5.2M |
| Sales, general & admin | $497,000 | $389,000 | $1.2M | $1.0M | $1.2M | $4.2M | $948,000 | $1.2M | $1.6M | $1.6M | $1.9M | $1.6M |
| Total operating expenses | $497,000 | $389,000 | $1.2M | $1.0M | $1.3M | $5.0M | $1.8M | $2.2M | $3.6M | $7.3M | $5.8M | $6.9M |
| Operating income | −$418,000 | −$246,000 | −$1.1M | −$992,000 | −$1.3M | −$5.0M | −$1.8M | −$2.2M | −$3.6M | −$7.3M | −$5.8M | −$6.8M |
| Interest income | — | $9,000 | $45,000 | $9,000 | $2,000 | $6,000 | — | $8,000 | — | — | — | — |
| Interest expense | — | — | — | — | — | — | — | — | $28,000 | — | — | — |
| Income before taxes | −$396,000 | −$167,000 | −$606,000 | −$988,000 | −$1.3M | −$81,000 | −$1.9M | −$2.2M | −$3.7M | −$7.2M | −$6.1M | −$6.7M |
| Income taxes | $9,000 | $30,000 | $5,000 | — | $2,000 | — | $1.2M | −$210,000 | −$412,000 | −$4.3M | −$822,000 | −$668,000 |
| Net income | −$405,000 | −$197,000 | −$611,000 | −$988,000 | −$1.3M | −$81,000 | −$3.1M | −$2.0M | −$3.3M | −$2.9M | −$5.3M | −$6.0M |
| EBITDA | −$417,000 | −$245,000 | −$1.1M | −$990,500 | −$1.3M | −$5.0M | −$1.9M | −$2.2M | −$3.6M | −$7.2M | −$6.1M | −$6.8M |
| EPS (diluted) | −$0.08 | −$0.04 | — | −$1.31 | −$1.53 | −$0.33 | — | −$43.20 | −$172.80 | −$544.80 | −$1495.31 | −$1764.00 |
| Gross margin | 23.5% | 18.4% | 18.2% | 21.0% | — | — | — | 100.0% | 100.0% | 93.1% | 74.2% | 56.2% |
| Operating margin | −124.4% | −31.6% | −162.5% | −1,224.7% | — | — | — | −21,770.0% | −91,100.0% | −25,103.4% | −18,580.6% | −42,781.2% |
| Net margin | −120.5% | −25.3% | −91.7% | −1,219.8% | — | — | — | −19,570.0% | −81,425.0% | −10,158.6% | −17,003.2% | −37,700.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in BGMS's financial statements (latest annual report filed December 31, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
BGMS financial results
In fiscal year 2025 (ended December 31, 2025), Bio Green Med Solution reported revenue of $0.7 million, up 1,637.2% from the year before. It had a net loss of $3.0 million, a net profit margin of −401.3%. Diluted earnings per share came to −$0.65.
See the BGMS stock overview for the latest quote and news, or the BGMS chart for price history and technical indicators.
BGMS income statement FAQ
What is Bio Green Med Solution's annual revenue?
Bio Green Med Solution reported total revenue of $0.7 million for fiscal year 2025, which ended on December 31, 2025. That was up 1,637.2% from $0.0 million the previous year.
Is Bio Green Med Solution profitable?
No. Bio Green Med Solution reported a net loss of $3.0 million in fiscal 2025, a net profit margin of −401.3%; its operating margin was −1,128.1%.
What is Bio Green Med Solution's gross margin?
Bio Green Med Solution's gross margin was 18.5% in fiscal 2025: for every $100 of revenue, Bio Green Med Solution kept $18 after the direct cost of its products and services.
How much does Bio Green Med Solution spend on research and development?
Bio Green Med Solution spent $0.8 million on research and development in fiscal 2025, 113.5% of revenue.
What are Bio Green Med Solution's earnings per share?
Bio Green Med Solution earned $-0.65 per diluted share in fiscal 2025, compared with $-291.22 a year earlier.
When will Bio Green Med Solution report its next earnings?
Bio Green Med Solution is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.
When does Bio Green Med Solution's fiscal year end?
Bio Green Med Solution's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on December 31, 2025.